ReviewAsian Pacific journal of cancer prevention : APJCP2025
The Role of Twisted Gastrulation 1 (TWSG1) Gene in TGF-β Signaling Linked to Cancer: A Comprehensive Review.
Review in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTransforming Growth Factor-beta (TGF-β) signaling is a crucial pathway in cancer development, affecting key processes such as cell growth, differentiation, and the spread of cancer cells. Recent research highlights the role of Twisted Gastrulation Protein Homolog 1 (TWSG1) as an important regulator of TGF-β signaling, showing both tumour-promoting and tumour-suppressing activities depending on the type of cancer and its specific context.
objectiveThis review provides a detailed overview of how TWSG1 influences TGF-β signaling in different cancers, including breast, colorectal, pancreatic, and lung. It also explores the potential of TWSG1 as a therapy target and as a biomarker for predicting patient outcomes.
methodsA thorough review of the current literature was conducted to understand how TWSG1 affects TGF-β signaling and its role in cancer progression. Studies were chosen based on their relevance to TWSG1's dual role in TGF-β signaling and its implications for cancer treatment.
resultsTWSG1 has been found to either enhance or inhibit TGF-β signaling. It can promote processes like epithelial-to-mesenchymal transition (EMT), cancer cell invasion, and metastasis by boosting interactions between TGF-β ligands and receptors and increasing SMAD protein phosphorylation. On the other hand, TWSG1 can also suppress TGF-β signaling by binding to the ligands, preventing them from interacting with receptors. High levels of TWSG1 are often associated with worse outcomes in several types of cancer, suggesting its potential as a biomarker and a target for cancer therapy.
conclusionTWSG1 plays a complex role in TGF-β signaling that varies with the type of cancer and the surrounding environment. Targeting TWSG1, either alone or alongside TGF-β inhibitors, could offer new avenues for treating cancers driven by TGF-β signaling. More research is needed to fully understand how TWSG1 is regulated and to explore its potential for use in clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.